Sight Sciences: Draft Medicare LCDs propose no coverage restrictions for OMNI and SION

Sight Sciences, Inc.

Five MACs published draft LCDs on MIGS not proposing specific coverage criteria for OMNI (canaloplasty+trabeculotomy) or SION (goniotomy).
These procedures would remain eligible for Medicare in states covering 62% of Sight Sciences' 2023 Surgical Glaucoma revenue.
Draft LCDs propose non-coverage when an aqueous shunt/stent is performed with a MIGS procedure in the same eye at same time.
45-day comment period; finalization within 365 days. Company plans to engage with MACs, CMS, and clinical societies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.